Cargando…

Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy

BACKGROUND: Ventricular arrhythmias in patients with hypertrophic cardiomyopathy (HCM) may lead to sudden cardiac death (SCD). We aimed to investigate the relationship between electrocardiogram (ECG) indicators and the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy in HCM....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Nixiao, Cheng, Sijing, Niu, Hongxia, Gu, Min, Peng, Hui, Sun, Zhijun, Liu, Xi, Deng, Yu, Chen, Xuhua, Hua, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133535/
https://www.ncbi.nlm.nih.gov/pubmed/35647065
http://dx.doi.org/10.3389/fcvm.2022.882662
_version_ 1784713589013086208
author Zhang, Nixiao
Cheng, Sijing
Niu, Hongxia
Gu, Min
Peng, Hui
Sun, Zhijun
Liu, Xi
Deng, Yu
Chen, Xuhua
Hua, Wei
author_facet Zhang, Nixiao
Cheng, Sijing
Niu, Hongxia
Gu, Min
Peng, Hui
Sun, Zhijun
Liu, Xi
Deng, Yu
Chen, Xuhua
Hua, Wei
author_sort Zhang, Nixiao
collection PubMed
description BACKGROUND: Ventricular arrhythmias in patients with hypertrophic cardiomyopathy (HCM) may lead to sudden cardiac death (SCD). We aimed to investigate the relationship between electrocardiogram (ECG) indicators and the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy in HCM. METHODS: The HCM patients receiving ICD implantation were enrolled consecutively. QT interval correction (QTc) was calculated using Bazett's formula. Long or deep S wave in V4 lead was defined as duration time >50 ms and/or voltage amplitude >0.6 mV. The endpoint in our study was at least one ICD appropriate therapy triggered by ventricular tachyarrhythmia (VT) or ventricular fibrillation (VF), including anti-tachyarrhythmia pacing (ATP) and electrical shock. RESULTS: A total of 149 patients with HCM (mean age 53 ± 14 years, male 69.8%) were studied. Appropriate ICD therapies occurred in 47 patients (31.5%) during a median follow-up of 2.9 years. Cox regression analysis showed that long or deep S wave in V4 lead [hazard ratio (HR) 1.955, 95% confidence interval (CI) 1.017–3.759, P = 0.045] and QTc interval (HR 1.014, 95% CI 1.008–1.021, P < 0.001) were independent risk factors for appropriate ICD therapy. The ROC showed that the optimal cut-off point value for the QTc interval to predict the appropriate ICD therapy was 464 ms, and the AUC was 0.658 (95% CI 0.544–0.762, P = 0.002). The AUC for S wave anomalies in V4 lead was 0.608 (95% CI 0.511–0.706, P = 0.034). We developed a new model that combined the QTc interval and S wave anomalies in V4 lead based on four patient groups. Patients with QTc ≥464 ms and long or deep V4-S wave had the highest risk of developing appropriate ICD therapy (log-rank P < 0.0001). After adding QTc interval and V4-S wave anomalies into the HCM-risk-SCD model, the prediction effect of the new model was significantly improved, and the NRI was 0.302. CONCLUSIONS: In this HCM cohort, QTc and S wave anomalies in V4 lead were found to be significant and strong predictors of the risk of appropriate ICD therapy. Patients with QTc ≥464 ms and long or deep S wave had the highest risk. After QTc interval and V4-S wave anomalies adding to the HCM-risk-SCD model, the prediction effect is significantly improved.
format Online
Article
Text
id pubmed-9133535
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91335352022-05-27 Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy Zhang, Nixiao Cheng, Sijing Niu, Hongxia Gu, Min Peng, Hui Sun, Zhijun Liu, Xi Deng, Yu Chen, Xuhua Hua, Wei Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Ventricular arrhythmias in patients with hypertrophic cardiomyopathy (HCM) may lead to sudden cardiac death (SCD). We aimed to investigate the relationship between electrocardiogram (ECG) indicators and the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy in HCM. METHODS: The HCM patients receiving ICD implantation were enrolled consecutively. QT interval correction (QTc) was calculated using Bazett's formula. Long or deep S wave in V4 lead was defined as duration time >50 ms and/or voltage amplitude >0.6 mV. The endpoint in our study was at least one ICD appropriate therapy triggered by ventricular tachyarrhythmia (VT) or ventricular fibrillation (VF), including anti-tachyarrhythmia pacing (ATP) and electrical shock. RESULTS: A total of 149 patients with HCM (mean age 53 ± 14 years, male 69.8%) were studied. Appropriate ICD therapies occurred in 47 patients (31.5%) during a median follow-up of 2.9 years. Cox regression analysis showed that long or deep S wave in V4 lead [hazard ratio (HR) 1.955, 95% confidence interval (CI) 1.017–3.759, P = 0.045] and QTc interval (HR 1.014, 95% CI 1.008–1.021, P < 0.001) were independent risk factors for appropriate ICD therapy. The ROC showed that the optimal cut-off point value for the QTc interval to predict the appropriate ICD therapy was 464 ms, and the AUC was 0.658 (95% CI 0.544–0.762, P = 0.002). The AUC for S wave anomalies in V4 lead was 0.608 (95% CI 0.511–0.706, P = 0.034). We developed a new model that combined the QTc interval and S wave anomalies in V4 lead based on four patient groups. Patients with QTc ≥464 ms and long or deep V4-S wave had the highest risk of developing appropriate ICD therapy (log-rank P < 0.0001). After adding QTc interval and V4-S wave anomalies into the HCM-risk-SCD model, the prediction effect of the new model was significantly improved, and the NRI was 0.302. CONCLUSIONS: In this HCM cohort, QTc and S wave anomalies in V4 lead were found to be significant and strong predictors of the risk of appropriate ICD therapy. Patients with QTc ≥464 ms and long or deep S wave had the highest risk. After QTc interval and V4-S wave anomalies adding to the HCM-risk-SCD model, the prediction effect is significantly improved. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9133535/ /pubmed/35647065 http://dx.doi.org/10.3389/fcvm.2022.882662 Text en Copyright © 2022 Zhang, Cheng, Niu, Gu, Peng, Sun, Liu, Deng, Chen and Hua. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Zhang, Nixiao
Cheng, Sijing
Niu, Hongxia
Gu, Min
Peng, Hui
Sun, Zhijun
Liu, Xi
Deng, Yu
Chen, Xuhua
Hua, Wei
Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy
title Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy
title_full Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy
title_fullStr Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy
title_full_unstemmed Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy
title_short Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy
title_sort association of qtc interval and v4-s wave with appropriate icd therapy in hypertrophic cardiomyopathy
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133535/
https://www.ncbi.nlm.nih.gov/pubmed/35647065
http://dx.doi.org/10.3389/fcvm.2022.882662
work_keys_str_mv AT zhangnixiao associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT chengsijing associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT niuhongxia associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT gumin associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT penghui associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT sunzhijun associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT liuxi associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT dengyu associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT chenxuhua associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy
AT huawei associationofqtcintervalandv4swavewithappropriateicdtherapyinhypertrophiccardiomyopathy